VERONA PHARMA PLC's ticker is VRNA and the CUSIP is 925050106. A total of 100 filers reported holding VERONA PHARMA PLC in Q3 2023. The put-call ratio across all filers is 3.08 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $91,031,474 | -22.9% | 5,108,563 | 0.0% | 7.03% | -22.0% |
| Q2 2023 | $118,061,678 | +5.3% | 5,108,563 | -8.5% | 9.01% | +16.3% |
| Q1 2023 | $112,141,840 | -23.2% | 5,584,753 | 0.0% | 7.75% | -5.5% |
| Q4 2022 | $145,929,596 | +155.7% | 5,584,753 | 0.0% | 8.20% | +187.9% |
| Q3 2022 | $57,076,000 | +166.6% | 5,584,753 | +9.3% | 2.85% | +159.2% |
| Q2 2022 | $21,405,000 | -16.0% | 5,108,563 | 0.0% | 1.10% | +49.3% |
| Q1 2022 | $25,492,000 | -25.7% | 5,108,563 | 0.0% | 0.74% | +6.1% |
| Q4 2021 | $34,330,000 | +22.8% | 5,108,563 | 0.0% | 0.69% | +109.0% |
| Q3 2021 | $27,950,000 | -16.3% | 5,108,563 | 0.0% | 0.33% | -23.7% |
| Q2 2021 | $33,410,000 | -21.8% | 5,108,563 | 0.0% | 0.44% | -54.6% |
| Q1 2021 | $42,708,000 | +19.4% | 5,108,563 | 0.0% | 0.96% | +1.6% |
| Q4 2020 | $35,760,000 | +12.2% | 5,108,563 | 0.0% | 0.94% | -30.1% |
| Q3 2020 | $31,877,000 | +458.5% | 5,108,563 | +318.8% | 1.35% | +489.5% |
| Q2 2020 | $5,708,000 | +13.6% | 1,219,674 | 0.0% | 0.23% | -12.9% |
| Q1 2020 | $5,025,000 | -28.3% | 1,219,674 | 0.0% | 0.26% | -20.8% |
| Q4 2019 | $7,013,000 | +25.8% | 1,219,674 | 0.0% | 0.33% | -28.1% |
| Q3 2019 | $5,574,000 | -10.4% | 1,219,674 | 0.0% | 0.46% | +6.0% |
| Q2 2019 | $6,220,000 | -21.5% | 1,219,674 | 0.0% | 0.44% | +5.8% |
| Q1 2019 | $7,926,000 | -27.8% | 1,219,674 | 0.0% | 0.41% | -5.3% |
| Q4 2018 | $10,977,000 | -28.1% | 1,219,674 | 0.0% | 0.44% | -33.9% |
| Q3 2018 | $15,258,000 | -8.4% | 1,219,674 | 0.0% | 0.66% | -15.7% |
| Q2 2018 | $16,661,000 | -31.7% | 1,219,674 | 0.0% | 0.78% | -28.0% |
| Q1 2018 | $24,393,000 | +68.5% | 1,219,674 | 0.0% | 1.08% | +80.8% |
| Q4 2017 | $14,478,000 | -22.7% | 1,219,674 | 0.0% | 0.60% | -8.5% |
| Q3 2017 | $18,722,000 | +141.0% | 1,219,674 | +83.0% | 0.66% | +131.8% |
| Q2 2017 | $7,770,000 | – | 666,666 | – | 0.28% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 1,332,485 | $34,817,833 | 22.99% |
| Abingworth LLP | 2,457,500 | $64,214,475 | 20.92% |
| Fairmount Funds Management LLC | 2,875,526 | $75,137,494 | 11.92% |
| Octagon Capital Advisors LP | 2,468,000 | $64,488,840 | 10.04% |
| NEA Management Company, LLC | 5,584,753 | $145,929,596 | 8.20% |
| Knoll Capital Management, LLC | 95,391 | $2,492,567 | 5.62% |
| Frazier Life Sciences Management, L.P. | 2,815,720 | $73,574,764 | 4.57% |
| Resolute Capital Asset Partners LLC | 185,992 | $4,860 | 4.34% |
| Caligan Partners LP | 183,064 | $4,783,462 | 3.98% |
| Samsara BioCapital, LLC | 695,001 | $18,160,376 | 3.91% |